Dear E, Biotech and big pharma companies face complex issues that are constantly evolving by the day. Looming patent cliffs, diminishing R&D budgets, and a myriad of evolving factors that drive consumer expectations are disrupting the traditional healthcare paradigm and impacting operations in unforeseen ways. Before mapping out a plan that can potentially change the direction and fate of a company, there are a few fundamental decisions that all biotech, mid-sized and big pharma leadership must make to ensure their success. |
|
|
| What Critical Decisions Must All Biotech Leadership Make? Prioritize, Consolidate, and Refine R&D Investment Through Strategic Portfolio/Pipeline Planning to Deliver the Greatest Overall Value to Your Company and Shareholders |
|
|
Anirvan Ghosh, Ph.D.,,
Senior Vice President, Head of Research and Early Development, BIOGEN |
|---|
| Sandy Macrae,,
CEO, SANGAMO THERAPEUTICS |
|---|
| Joanna Wolkowski,,
Vice President, Portfolio and Decision Analysis, PFIZER |
|---|
|
|---|
|
Pearl S. Huang, Ph.D.,,
President and CEO, CYGNAL THERAPEUTICS |
|---|
| Frederic Chereau,,
CEO, LOGICBIO THERAPEUTICS |
|---|
|
|---|
|
| Build Vs. Buy: Key Considerations for Deciding Whether to Commercialize on Your Own or Find a Strategic Partner |
|
|
Amirah Al Idrus,,
Editor, FIERCEBIOTECH |
|---|
| Molly Harper,,
Senior Vice President and Global Franchise General Manager, AKCEA THERAPEUTICS |
|---|
| Rich Daly,,
Chief Operating Officer, BEYONDSPRING PHARMACEUTICALS |
|---|
|
|---|
|
Marcio Souza,,
Chief Operating Officer, PTC THERAPEUTICS |
|---|
| Jeffrey Bova,,
Senior Vice President, Commercial, UROGEN PHARMA |
|---|
|
|---|
|
Join your peers at the 4th FierceBiotech Drug Development Forum to learn how companies think through key decision-making, adapt effectively in the face of change and uncertainty, and chart out a plan for development, regulatory, and financial success for a life science company. |
|
|
| Thank you to our 2019 sponsors! |
|
|
|
